Humanized CRISPRa system and application thereof
By designing a humanized CRISPRa system, the fusion of human transcriptional activation protein and dCas protein is solved, and the existing CRISPRa system has been achieved with low immunogenicity and transcriptional activation effects in clinical applications, achieving high efficiency and low immunogenicity Gene activation, suitable for clinical treatment.
Patent Information
- Application Number
- CN202411005790.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-24
- Publication Date
- 2024-12-06
AI Technical Summary
The existing CRISPRa system faces immunogenicity problems in clinical applications, resulting in low transcriptional activation effects in mammalian cells and dependent on the domain of virus origin, affecting its safety and effectiveness.
A humanized CRISPRa system was designed to form a low immunogenic and efficient CRISPRa system, including dCas proteins and a variety of human transcriptional activation proteins by fusing dCas proteins that lose endonuclease activity with human transcriptional activation proteins. Combinations such as MRTF-A, STAT1, eNRF2, NCOA3, FOXO3, ZN473, p65, HSF1 and CITED2 bind to guide RNA for efficient activation of targeted genes.
It realizes efficient transcriptional activation in mammalian cells, has low immunogenicity, and the activation effect is close to or exceeds that of the dCas-VPR system. The system is simple, only contains guide RNA and fusion protein, which is easy to operate, and has lower immunogenicity. and smaller volumes.
Smart Images

Figure BDA0004963564740000051 
Figure BDA0004963564740000061 
Figure BDA0004963564740000062
Abstract
Description
Technical Field
[0001] The present application relates to the field of genetic engineering technology, and in particular to a humanized CRISPRa system and its application. Background Art
[0002] Many genetic diseases are caused by gene mutations, but in many cases these mutant genes have silent alleles. Transcriptional activation of these silent functional genes to compensate for the function of the mutant genes is an effective treatment strategy. Transcriptional regulation is an important part of gene expression in eukaryotes, and this process involves the joint participation of many transcriptional regulatory proteins. Among them, transcription factors can promote the interaction between RNA polymerase and promoter, increase the transcription level of target genes, and play an important role in regulating cell behavior and determining cell fate. Artificial transcription factors (aTFs) can be designed and constructed by re-integrating the transcription activation domain (TAD) and the programmable DNA binding domain. In recent years, artificial transcription factors derived from CRISPR / Cas9 gene editing technology have been reported one after another. Currently, the commonly used CRISPR activation (CRIPSR activation, CRIPSRa) systems include dCas9-VP64, dCas9-SunTag, dCas9-SAM, dCas9-VPR, etc. These transcription activation systems can achieve precise regulation of gene expression without changing the gene sequence, and are expected to bring new treatments for genetic diseases, chronic diseases and infectious diseases that currently have no effective treatment options.
[0003] In the first generation of CRISPRa system, dCas9 was fused with the typical viral TAD VP64 (tetramer of VP16), but the transcriptional activation effect of dCas9-VP64 in mammalian cells was low. Konermann et al. established dCas9-SAM (synergistic activation mediator) based on the basic dCas9-VP64 structure. dCas9-SAM achieves targeted activation of gene transcription by co-expressing dCas9-VP64, sgRNA with hairpin structure and MCP-p65-HSF1 fusion protein. dCas9-Suntag developed by Tanenbaum et al. fuses dCas9 with polypeptide GCN4s. GCN4s can recruit multiple homologous single-chain variable fragments scFv (single-chain variable fragment). By fusing scFv to VP64, dCas9 can recruit up to 24 VP64 activation factors. The dCas9-VPR developed later is a fusion of dCas9 with VP64, p65 and Rta (human herpes virus replication and transcription activator). The activation efficiency of dCas9-VPR on endogenous genes can reach tens to hundreds of times that of the dCas9-VP64 system. The newly reported dCas9-DREAM is based on the dCas9-SAM system, which fuses TADs from human proteins MRTF-A, STAT1 and eNRF2 with the MS2 phage capsid protein MCP, which can effectively increase the expression of endogenous genes.
[0004] Although the existing CRISPRa system has been proven to be able to effectively regulate transcription in a variety of cells, it still encounters some challenges in clinical application. Existing CRISPRa systems all rely on viral domains to achieve efficient transcriptional activation, and their potential immunogenicity hinders the clinical transformation of CRISPRa systems. Humanized CRISPRa systems with high efficiency and low immunogenicity are expected to provide safer tools and methods for future clinical treatments. Summary of the invention
[0005] Based on this, it is necessary to provide a humanized CRISPRa system in one embodiment of the present application, which specifically comprises a Cas fusion protein and a guide RNA, has low immunogenicity, and can achieve efficient transcriptional activation of the target gene.
[0006] The technical solution is as follows:
[0007] Cas fusion protein, comprising dCas protein and human transcriptional activator protein, wherein:
[0008] The dCas protein is a Cas protein that has lost endonuclease activity;
[0009] The human transcriptional activation protein is selected from a variety of combinations of MRTF-A, STAT1, eNRF2, NCOA3, FOXO3, ZN473, p65, HSF1 and CITED2 transcriptional activation domains.
[0010] The humanized CRISPRa system comprises the fusion protein and one or more guide RNAs.
[0011] A host cell comprises the CRISPRa system, and the genome of the host cell contains a target gene recognized by the guide RNA.
[0012] The isolated nucleic acid comprises a nucleic acid encoding the fusion protein, and optionally, also comprises the guide RNA in the CRISPRa system.
[0013] A vector comprising the nucleic acid.
[0014] A method for activating transcription of a target gene in a host, comprising the step of introducing the CRISPRa system, the nucleic acid, or the vector into the host.
[0015] The fusion protein, the CRISPRa system, the host cell, the nucleic acid and the vector are used in the preparation of gene therapy drugs.
[0016] A pharmaceutical composition comprises the fusion protein, the CRISPRa system, the host cell, the nucleic acid or the vector, and a pharmaceutically acceptable carrier.
[0017] Compared with the traditional technology, this application has the following beneficial effects:
[0018] The fusion protein and CRISPRa system constructed by the present invention do not contain virus-derived domains, maximize the use of human proteins, have lower immunogenicity, can be used to activate endogenous genes, and have an activation effect close to or exceeding that of dCas-VPR, and are smaller in size.
[0019] The CRISPRa system constructed by the present invention has a simple structure, comprising only two parts, a guide RNA and a fusion protein, and is easy to operate when activating endogenous genes. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1Activation of GFP reporter gene by human transcription activator proteins. (a) Schematic diagram of the composition of the CRISPRa system. (b) Schematic diagram of the human and viral transcription activation domains screened. (c) Schematic diagram of GFP reporter gene plasmid, dCas9 fusion protein plasmid and sgRNA plasmid. (d) Activation ratio of GFP reporter gene by different dCas9 fusion proteins. (e) Activation ratio of GFP reporter gene by different dCas9 fusion proteins in BFP-positive cells.
[0021] Figure 2 The transcriptional activation of endogenous genes by a combination of multiple transcriptional activator proteins. HEK293T cells were co-transfected with dCas9-TADs and sgRNAs targeting HBG (a), TTN (b), IL1B (c), ASCL1 (d), SOX2 (e), or NEUROD1 (f). Cells were collected 72 hours after transfection for RNA extraction and qRT-PCR detection. GAPDH was used as an internal reference gene, and 4 sgRNAs were used for each gene to target the region near the transcription start site. The data are plotted as mean ± SEM and represent three biological replicates. The expression level of dCas9 in the control group was set to 1.0.
[0022] Figure 3 The transcriptional activation of endogenous genes by various combinations of human transcriptional activation domains. (a) Schematic diagram of the humanized CRISPRa system. (b) Protein expression of different Cas fusion proteins. (cd) qRT-PCR detection of transcriptional activation of endogenous genes HBG (c) and TTN (d). GAPDH was used as an internal reference gene, and 4 sgRNAs were used to target the region near the transcription start site for each gene. M: MSN; N: NFZ; P: p65HSF1; C: CITED2. Data are plotted as mean ± SEM. The expression level of dCas9 in the control group was set to 1.0, and significance indicates the significance analysis compared with the VPR group, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, ns, no significant difference.
[0023] Figure 4The optimized human transcriptional activation domain was applied to various Cas systems for activating endogenous genes. (ad) The activation efficiency of dCas9-TAD in activating endogenous genes IL1B (a), ASCL1 (b), SOX2 (c) and NEUROD1 (d) was detected by qRT-PCR. (e) Schematic diagram of dCasMINI system plasmid construction; (fg) The activation efficiency of dCasMINI-TAD in activating endogenous genes HBG (f) and ASCL1 (g) was detected by qRT-PCR. GAPDH was used as an internal reference gene, and 1 or 4 sgRNAs were used to target the region near the transcription start site for each gene. M: MSN; N: NFZ; P: p65HSF1; C: CITED2. Data are plotted as mean ± SEM. The expression level of dCas9 in the control group was set to 1.0, and the significance indicated the significance analysis compared with the VPR group, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, ns, no significant difference.
[0024] Figure 5 Analysis of the activation specificity of human transcriptional effector proteins by transcriptome sequencing. (a) Schematic diagram of sgRNA targeting positions. (b) Relative fold change of gene expression in the dCas9-NP group. (c) Relative fold change of gene expression in the dCas9-VPR group. (d) Comparison of the dCas9-NP group and the dCas9-VPR group. Negative control group, dCas9. Data represent the average of two independent biological replicates.
[0025] Figure 6 Prediction of immunogenicity scores for transcriptional effector proteins. The red dashed box marks the non-human amino acid sequence. DETAILED DESCRIPTION
[0026] In order to make the above-mentioned purposes, features and advantages of the present application more obvious and easy to understand, the specific implementation methods of the present application are described in detail below. In the following description, many specific details are set forth to facilitate a full understanding of the present application. However, the present application can be implemented in many other ways different from those described herein, and those skilled in the art can make similar improvements without violating the connotation of the present application, so the present application is not limited by the specific embodiments disclosed below.
[0027] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art to which this application belongs. The terms used herein in the specification of this application are only for the purpose of describing specific embodiments and are not intended to limit this application.
[0028] As used herein, the term "and / or" includes any and all combinations of one or more of the associated listed items.
[0029] The term "plurality" as used herein, unless otherwise specified, refers to a number greater than 2 or equal to 2.
[0030] This application systematically compares the transcriptional activation efficiency of newly identified human transcriptional activators, commonly used viral transcriptional activators, and synthetic transcriptional activators in mammalian cells. In order to develop a minimally immunogenic and compact CRISPRa tool, this application explores the synergistic effects of effective human transcriptional activators, including MRTF-A / STAT1 / eNRF2 (MSN), NCOA3 / FOXO3 / ZNF473 (NFZ), p65HSF1, and CITED2-TAD. Directly fusing dCas proteins with efficient human transcriptional activators can achieve efficient activation of target genes in mammalian cells under the guidance of guide RNA, including genes used in the test and other genes. The results show that NFZ-p65HSF1 (NP), CITED2-MSN (CM), and CITED2-NFZ (CN) fusions can efficiently activate endogenous gene expression in mammalian cells, and the activation efficiency is comparable to that of the synthetic transcriptional activator protein VPR, and the predicted immunogenicity is lower and the size is smaller. In addition, the newly developed fusion human effector protein combination is compatible with the mini-Cas system (dCasMINI), which is conducive to the delivery of viral vectors in primary cells and in vivo.
[0031] Based on this, one embodiment of the present application provides a fusion protein, which does not contain a protein domain of viral origin, maximizes the use of human proteins, has lower immunogenicity, and can achieve efficient activation of endogenous genes several to tens of thousands of times, and comprises a dCas protein and a human transcription activator protein, wherein the dCas protein is a Cas protein that has lost endonuclease activity; the human transcription activator protein is selected from MRTF-A (Myocardin related transcription factor A), STAT1 (Signal transducer and activator of transcription 1), eNRF2 (Nuclear factor-erythroid 2-related factor 2), NCOA3 (Nuclear receptor coactivator 3), FOXO3 (Forkhead box protein O3), ZN473 (Zincfinger protein 473), p65 (Nuclear factor Various combinations of NF-kappa-B p65 subunit (nuclear transcription factor-kappa-B p65), HSF1 (Heat shock factor protein 1) and CITED2 (Cbp / p300-interacting transactivator 2). Human transcription activators are used to recruit transcription regulatory factors and promote transcription of target genes. The various transcription activators provided in this application also provide more selectivity for gene activation.
[0032] In a specific example, the human transcriptional activator protein is selected from any two combinations of the following groups:
[0033] Group 1: MRTF-A, STAT1, and eNRF2 transcriptional activation domain;
[0034] Group 2: NCOA3, FOXO3, and ZN473 transcriptional activation domains;
[0035] Group 3: p65 and HSF1 transcriptional activation domains;
[0036] Group 4: CITED2 transcriptional activation domain.
[0037] Optionally, the human transcription activator protein is a combination of NCOA3, FOXO3, ZN473, p65 and HSF1 transcription activation domains, a combination of CITED2, MRTF-A, STAT1 and eNRF2 transcription activation domains, or a combination of CITED2, NCOA3, FOXO3 and ZN473 transcription activation domains.
[0038] In the present application, dCas proteins include a variety of different CRISPR / Cas proteins that have lost their endonuclease activity. Different dCas proteins are used with different specific targeting sites and PAM recognition sequences, so they can widely cover the sites of various genes and have great applicability.
[0039] In a specific example, the dCas protein includes but is not limited to a dCas9 protein and / or a dCas12 protein.
[0040] Optionally, the dCas12 protein includes a dCas12f protein. The use of the relatively small dCas12f (529aa) nuclease currently solves the problem of the system being too large for use in vivo and in vitro.
[0041] Optionally, the dCas9 protein contains D10A and H840A mutations compared to the Cas9 protein.
[0042] Optionally, the source of Cas9 protein includes but is not limited to Streptococcus pyogenes. Optionally, the Cas9 protein is Streptococcus pyogenes Cas9 protein (Streptococcus pyogenes Cas9).
[0043] Optionally, the dCas9 protein includes a fragment as shown in amino acid position 1 to amino acid position 1368 in SEQ NO.1.
[0044] Optionally, the dCas12f protein contains one or more mutations of D326A, D510A, D143R, T147R, K330R and E528R compared to the Cas12f protein.
[0045] Optionally, the Cas12f protein includes a fragment as shown in amino acid position 1 to amino acid position 529 in SEQ NO.4.
[0046] In a specific example, from N-terminus to C-terminus, the fusion protein comprises a dCas protein, a nuclear localization signal, and a human transcriptional activator protein.
[0047] Optionally, from N-terminus to C-terminus, the fusion protein comprises a dCas protein, a nuclear localization signal, a NCOA3 transcriptional activation domain, a FOXO3 transcriptional activation domain, a ZN473 transcriptional activation domain, a p65 transcriptional activation domain, and a HSF1 transcriptional activation domain.
[0048] Optionally, from N-terminus to C-terminus, the fusion protein comprises a dCas protein, a nuclear localization signal, a CITED2 transcriptional activation domain, a MRTF-A transcriptional activation domain, a STAT1 transcriptional activation domain, and an eNRF2 transcriptional activation domain.
[0049] Optionally, from N-terminus to C-terminus, the fusion protein comprises a dCas protein, a nuclear localization signal, a CITED2 transcriptional activation domain, a NCOA3 transcriptional activation domain, a FOXO3 transcriptional activation domain, and a ZN473 transcriptional activation domain.
[0050] In a specific example, the amino acid sequence of the NCOA3 transcriptional activation domain includes the sequence shown in amino acids 1379 to 1426 in SEQ NO.1, the amino acid sequence of the FOXO3 transcriptional activation domain includes the sequence shown in amino acids 1433 to 1473 in SEQ NO.1, the amino acid sequence of the ZN473 transcriptional activation domain includes the sequence shown in amino acids 1480 to 1520 in SEQ NO.1, the amino acid sequence of the p65 transcriptional activation domain includes the sequence shown in amino acids 1526 to 1706 in SEQ NO.1, the amino acid sequence of the HSF1 transcriptional activation domain includes the sequence shown in amino acids 1715 to 1838 in SEQ NO.1, the amino acid sequence of the CITED2 transcriptional activation domain includes the sequence shown in amino acids 1379 to 1438 in SEQ NO.3, and the amino acid sequence of the MRTF-A transcriptional activation domain includes the sequence shown in SEQ NO. The amino acid sequence of the STAT1 transcriptional activation domain includes the sequence shown from amino acid position 1633 to amino acid position 1668 in SEQ NO.3, and the amino acid sequence of the eNRF2 transcriptional activation domain includes the sequence shown from amino acid position 1671 to amino acid position 1733 in SEQ NO.3.
[0051] In a fusion protein, two protein structural regions are connected by a connecting peptide (amino acid peptide chain).
[0052] In a specific example, the number of amino acids in the connecting peptide is 1 to 30, which can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30.
[0053] In a specific example, the connecting peptide is a flexible connecting peptide; in a specific example, the amino acid sequence of the connecting peptide includes one or more of G (Gly, glycine), S (Ser, serine), Q (Gln, glutamine), A (Ala, alanine), T (Thr, threonine), E (Glu, glutamate), F (Phe, phenylalanine), and R (Arg, arginine).
[0054] In a specific example, the amino acid sequence of the connecting peptide is selected from (GSATEFSR)n, (SGQGGGGS)n, (GGGGS)n, (GGGS)n, (GGS)n, (GS)n, (AS)n, (G)n or (A)n, wherein n is selected from 1, 2, 3, 4, 5 or 6.
[0055] In a specific example, the fusion protein comprises an amino acid fragment shown in any one of SEQ NO. 1 to 6. Optionally, the fusion protein comprises an amino acid fragment that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in any one of SEQ NO. 1 to 6.
[0056] Proteins with similar protein sequence changes based on the structure of the fusion protein and having the same function are within the scope of this application.
[0057] One embodiment of the present application provides a CRISPRa system, comprising the fusion protein and one or more guide RNAs.
[0058] In a specific example, the guide RNA includes a fragment that recognizes the target gene. Under the guidance of the guide RNA, the fusion protein can accurately locate the region within 500 base pairs upstream or downstream of the transcription start site of the target gene. After the fusion protein is located at a specific genomic site, the target gene is regulated by initiating transcription to achieve the purpose of activating gene expression.
[0059] In a specific example, the target gene includes at least one of TTN, HBG, NEUROD1, ASCL1, IL1B and SOX2.
[0060] In one specific example, the one or more guide RNAs include guide RNAs targeting one or more target genes. Alternatively, the plurality of guide RNAs include a plurality of guide RNAs targeting a single target gene.
[0061] Optionally, the guide RNA targeting TTN includes at least one of the sequences shown in SEQ NO.7-10. Optionally, the guide RNA targeting HBG includes at least one of the sequences shown in SEQ NO.11-14 or the sequence shown in SEQ NO.31. Optionally, the guide RNA targeting NEUROD1 includes at least one of the sequences shown in SEQ NO.15-18. Optionally, the guide RNA targeting ASCL1 includes at least one of the sequences shown in SEQ NO.19-22 or the sequence shown in SEQ NO.32. Optionally, the guide RNA targeting IL1B includes at least one of the sequences shown in SEQ NO.23-26. Optionally, the guide RNA targeting SOX2 includes at least one of the sequences shown in SEQ NO.27-30.
[0062] One embodiment of the present application also provides a host cell, comprising the CRISPRa system, and the genome of the host cell contains the target gene recognized by the guide RNA.
[0063] In one specific example, the host cell is a mammalian cell. Optionally, the mammal is a human.
[0064] One embodiment of the present application also provides an isolated nucleic acid encoding the fusion protein.
[0065] In one specific example, the nucleic acid also has a nuclear localization signal sequence (NLS), and optionally, the NLS is linked to the Cas protein nucleic acid.
[0066] Optionally, the nucleic acid is codon optimized for more efficient expression in the cell.
[0067] In a specific example, the nucleic acids encoding the amino acid fragments shown in SEQ NOs. 1 to 6 are shown in SEQ NOs. 47 to 52, respectively.
[0068] One embodiment of the present application further provides a vector, which contains the nucleic acid and a guide RNA that recognizes the target gene. Optionally, the vector includes a plasmid and / or a virus, and optionally, the plasmid includes a pGL3 series, and optionally, the virus includes an adeno-associated virus vector.
[0069] One embodiment of the present application also provides a method for activating transcription of a target gene in a host, the method comprising the step of introducing the CRISPRa system, the nucleic acid, or the vector into the host. Optionally, it also comprises expressing the fusion protein in the host and cooperating with the guide RNA to activate the target gene. Optionally, the host comprises a mammal, a mammalian tissue, or a mammalian cell.
[0070] One embodiment of the present application also provides the use of the fusion protein, the CRISPRa system, the host cell, the nucleic acid, and the vector in the preparation of gene therapy drugs.
[0071] One embodiment of the present application also provides a pharmaceutical composition, comprising the fusion protein, the CRISPRa system, the host cell, the nucleic acid, or the vector, and a pharmaceutically acceptable carrier.
[0072] The embodiments of the present application will be described in detail below in conjunction with examples. It should be understood that these examples are only used to illustrate the present application and are not intended to limit the scope of the present application. The experimental methods for which specific conditions are not specified in the following examples are preferably referred to the guidance provided in the present application, and can also be based on the experimental manual or normal conditions in this area, can also be based on the conditions recommended by the manufacturer, or refer to experimental methods known in the art.
[0073] In the following specific embodiments, the measured parameters of raw material components may have slight deviations within the range of weighing accuracy unless otherwise specified. For temperature and time parameters, acceptable deviations caused by instrument test accuracy or operation accuracy are allowed.
[0074] The experimental methods involved in the following examples include the following:
[0075] 1. Plasmid Construction
[0076] Plasmid cloning was performed using standard molecular cloning techniques. pAC1410 (Addgene #71907) was used as the backbone plasmid for the construction of dCas9-TAD and dCasMINI-TAD. VP64 and VPR were amplified from pRS415-Cas9-VPR (Addgene #163971). CITED2-TAD, MRTF-A / STAT1 / eNRF2 (MSN), and NCOA3 / FOXO3 / ZNF473 (NFZ) amino acids were synthesized by Tianjin Jiutian Gene Co., Ltd. after human codon optimization. The sgRNA expression plasmid was constructed by ligating the corresponding annealed oligonucleotides to the backbone plasmid downstream of the human U6 promoter (Addgene #107721). All primers were synthesized by Hangzhou Youkang Biological Co., Ltd., and the first-generation Sanger sequencing was completed by Hangzhou Youkang and Hangzhou Shangya Biological Co., Ltd.
[0077] (2) Cell culture
[0078] Human embryonic kidney HEK293T (GNHu44) cell line was purchased from the National Authentication Cell Bank (Shanghai, China). HEK293T was cultured in DMEM high glucose medium (Gibco, USA), supplemented with 1% non-essential amino acids and GlutaMAX (Gibco, USA), and supplemented with 10% fetal bovine serum (ExCell Bio, China) and 5% penicillin / streptomycin. Cells were cultured in a cell culture incubator at 37°C with 5% CO2, and passaged every 3-4 days to keep the cell confluence below 90%.
[0079] (3) Cell transfection
[0080] All transient transfections were performed using polyethyleneimine (YEASEN, China). The total amount of DNA in each 24-well plate was 200 ng. 5 Cells were seeded in 24-well plates one day before transfection. For gene activation experiments, plasmids of dCas9-TAD and sgRNA were co-transfected at a ratio of 2:1. 10 hours after transfection, the medium was replaced with fresh complete growth medium. Transfected cells were analyzed for endogenous gene activation three days after transfection. The sequences of the sgRNAs used are listed in Table 1.
[0081] Table 1
[0082]
[0083]
[0084] (4) Fluorescence quantitative PCR (qRT-PCR)
[0085] RNA was extracted using Trizol reagent and reverse transcribed into cDNA using Prime Script RT kit (Takara, Japan). qRT-PCR was performed using SYBR Premix Ex Taq II (Takara, Japan) in an Applied Biosystems QuantStudioTM7Pro real-time polymerase chain reaction instrument (Thermo Fisher Scientific, USA). qRT-PCR amplification of each sample was performed in triplicate. ΔΔCt Methods Relative mRNA expression levels were calculated. The housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal reference gene. The qRT-PCR primers used are listed in Table 2.
[0086] Table 2
[0087]
[0088] Example 1 Comparison of activation abilities of transcription effector proteins from different sources
[0089] To systematically compare the activation abilities of viral-derived and human-derived transcriptional effector proteins, we constructed C-terminal fusion proteins of dCas9, including eight reported functional human-derived transcriptional activation domains, including KLF7-TAD, MYB-TAD, CSRNP1-TAD, CITED1-TAD, CITED2-TAD, p65HSF1, MSN, and NFZ, and two viral-derived transcriptional activation domains, including VP64 and VPR ( Figure 1 Middle a, Figure 1 We first tested the gene activation efficiency of these transcriptional activation domains of different origins relative to VP64 and VPR in HEK293T cells using an EGFP reporter gene driven by the minCMV minimal promoter located downstream of the eight sgRNA binding sites ( Figure 1 The results showed that the activation efficiency of human p65HSF1, MSN and CITED2-TAD was higher than that of VP64, but still weaker than that of VPR ( Figure 1 Middle d, Figure 1 e). To verify the reliability of this observation in the chromosomal context, we further studied the activation efficiency of p65HSF1, MSN, NFZ and CITED2-TAD on endogenous gene targets. We selected some genes that are therapeutic targets (HBG, IL1B and TTN) or encode transcription factors for cell differentiation (ASCL1, SOX2 and NEUROD1). On the third day after transfection with targeting sgRNAs and dCas9-TAD plasmids, the relative mRNA expression levels were detected by qRT-PCR. The results showed that these four human transcription activation domains had an activation effect on all the endogenous genes tested. Their relative activation levels varied among different target genes. Consistent with the results of the reporter gene analysis, the activation effect of the single human transcription activation domain combination CITED2-TAD, NFZ, MSN and p65HSF1 on all target genes was weaker than that of VPR ( Figure 2 ).
[0090] Example 2 Synergistic effects between transcriptional activation domains in human transcriptional effector proteins
[0091] In natural systems, transcription initiation occurs through the coordinated recruitment of necessary effector molecules by transcription factor activation domains. The tandem fusion of multiple transcription activation domains can simulate the natural coordinated recruitment process to improve the efficiency of transcription activation. Therefore, studying and screening the synergistic effects between novel transcription activation domains is an effective way to transform efficient transcription activation proteins.
[0092] In this example, a series of dCas-transcription activator fusion proteins (referred to as transcription effector proteins) were constructed, which contained p65HSF1 (referred to as P), MSN (referred to as M), NFZ (referred to as N), and CITED2-TAD (referred to as C). The two proteins were connected by a glycine-serine sequence ( Figure 3 (a). RNA extraction and qRT-PCR were used to detect the activation of endogenous genes HBG and TTN by different transcription activator combinations after fusion with dCas9, and the activation effects of different transcription activator combinations were compared. Compared with the negative control dCas9, the dCas9-transcription activator fusion protein can effectively increase the expression level of the fusion protein ( Figure 3 b), and they can effectively increase the expression level of the target gene. Among them, the more efficient ones are NFZ-p65HSF1 (NP, 460aa), MSN-CITED2 (MC, 355aa), CITED2-MSN (CM, 355aa) and CITED2-NFZ (CN, 207aa). The activation effects of these combinations are not significantly different from those of VPR, and their volumes are smaller than those of VPR (523aa). Figure 3 Middle c, Figure 3 (d)
[0093] Among them, the amino acid sequence of the constructed dCas and human transcription activator fusion protein and the nucleotide sequence information after codon optimization are shown in Table 3.
[0094] Table 3
[0095]
[0096]
[0097]
[0098] Example 3 Detection of activation efficiency of optimized human transcription activator protein combination
[0099] In order to further determine the activation stability of the above human transcriptional activator combination, the activation of four endogenous genes (IL1B, ASCL1, SOX2 and NEUROD1) was detected by qRT-PCR ( Figure 4ad in Chinese). The results showed that different human transcription effector proteins had different activation effects on different genes. For IL1B and ASCL1 genes, NP and CM combinations showed the highest activation efficiency, and both were significantly higher than VPR; but for SOX2 and NEUROD1 genes, the humanized combinations were not as effective as VPR. From the above results, it can be seen that the activation efficiency of the human transcription activator combination may be affected by the background expression level of the gene, and the activation effect of the cell differentiation-related transcription factors SOX2 and NEUROD1 is not as good as the compound protein VPR.
[0100] Example 4 Small Cas system application
[0101] dCasMINI was directly fused with NP, CM, CN and VPR, and its activation efficiency on endogenous genes HBG and ASCL1 was tested ( Figure 4 In the dCasMINI system, NP and CN still exhibit activation efficiencies close to or even exceeding those of VPR.
[0102] Among them, the amino acid sequence information of the constructed dCas and human transcription activator fusion proteins (dCasMINI-NP, dCasMINI-CN, dCasMINI-CM) is shown in Table 4.
[0103] Table 4
[0104]
[0105]
[0106] Example 5 Transcriptional Activation Specificity Analysis
[0107] In order to detect whether the activation effect of the transcriptional effector protein of the NP combination is specific, HEK293T cells were co-transfected with four sgRNAs targeting the HBG gene and dCas9, dCas9-NP or dCas9-VPR, and the cells were collected three days after transfection for transcriptome sequencing analysis. The number of differentially expressed genes in the transcriptome sequencing analysis of dCas9-NP vs ctrl and dCas9-VPR vs ctrl was similar, 120 and 76, respectively. Among them, the fold changes of HBG1 and HBG2 genes in the dCas9-NP vs ctrl group were 1206 times and 55,443 times, respectively, and the fold changes of HBG1 and HBG2 genes in the dCas9-VPR vs ctrl group were 375 times and 18,345 times, respectively, indicating that dCas9-NP has good activation specificity and activation efficiency ( Figure 5 ).
[0108] Example 6 Prediction of immunogenicity score
[0109] The immunogenicity scores of all 9 amino acid peptide sequences in human transcription effector proteins and transcription effector proteins containing viral proteins were evaluated using the T cell class I pMHC immunogenicity tool of the Immune Epitope Database (IEDB). A higher immunogenicity score indicates that the composition of the peptide is closer to the immunogenic peptide, indicating a higher possibility of triggering an immune response. The immunogenicity scores of non-human peptides in transcription effector proteins were analyzed by IEDB. There were 13, 10, and 8 fragments with NP, CM, and CN scores greater than 0, respectively, 21 and 130 fragments with VP64 and VPR scores greater than 0, and the number of fragments with scores greater than 0 for human transcription effector proteins was much less than that for VPR ( Figure 6 ). Therefore, the human transcriptional effector protein combination has lower immunogenicity than VPR.
[0110] The technical features of the above-described embodiments may be arbitrarily combined. To make the description concise, not all possible combinations of the technical features in the above-described embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.
[0111] The above-mentioned embodiments only express several implementation methods of the present application, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the invention patent. It should be pointed out that, for a person of ordinary skill in the art, several variations and improvements can be made without departing from the concept of the present application, and these all belong to the protection scope of the present application. Therefore, the protection scope of the patent of the present application shall be subject to the attached claims, and the description may be used to interpret the content of the claims.
Claims
1. Fusion protein, It is characterized in that Contains dCas protein and human transcriptional activator protein, wherein: The dCas protein is a Cas protein that has lost endonuclease activity; The human transcriptional activation protein is selected from a variety of combinations of MRTF-A, STAT1, eNRF2, NCOA3, FOXO3, ZN473, p65, HSF1 and CITED2 transcriptional activation domains.
2. The fusion protein according to claim 1, It is characterized in that The human transcription activator protein is selected from any two combinations of the following groups: Group 1: MRTF-A, STAT1, and eNRF2 transcriptional activation domain; Group 2: NCOA3, FOXO3, and ZN473 transcriptional activation domains; Group 3: p65 and HSF1 transcriptional activation domains; and, Group 4: CITED2 transcriptional activation domain; Optionally, the human transcriptional activator protein is a combination of NCOA3, FOXO3, ZN473, p65 and HSF1 transcriptional activation domains, a combination of CITED2, MRTF-A, STAT1 and eNRF2 transcriptional activation domains, or a combination of CITED2, NCOA3, FOXO3 and ZN473 transcriptional activation domains.
3. The fusion protein according to claim 2, It is characterized in that The fusion protein comprises, from the N-terminus to the C-terminus: the dCas protein, the nuclear localization signal and the human transcription activator protein; Optionally, the fusion protein comprises, from N-terminus to C-terminus: the dCas protein, a nuclear localization signal, a NCOA3 transcriptional activation domain, a FOXO3 transcriptional activation domain, a ZN473 transcriptional activation domain, a p65 transcriptional activation domain, and a HSF1 transcriptional activation domain; Optionally, the fusion protein comprises, from N-terminus to C-terminus: the dCas protein, a nuclear localization signal, a CITED2 transcriptional activation domain, an MRTF-A transcriptional activation domain, a STAT1 transcriptional activation domain, and an eNRF2 transcriptional activation domain; Optionally, the fusion protein comprises, from N-terminus to C-terminus: the dCas protein, a nuclear localization signal, a CITED2 transcriptional activation domain, a NCOA3 transcriptional activation domain, a FOXO3 transcriptional activation domain and a ZN473 transcriptional activation domain.
4. The fusion protein according to any one of claims 1 to 3, It is characterized in that The dCas protein includes dCas9 protein and / or dCas12 protein; Optionally, the dCas9 protein contains mutations D10A and H840A compared to the Cas9 protein; Optionally, the dCas12 protein includes a dCas12f protein, Compared with the Cas12f protein, the dCas12f protein contains one or more mutations of D326A, D510A, D143R, T147R, K330R and E528R.
5. The fusion protein according to any one of claims 1 to 3, It is characterized in that The amino acid sequence of the NCOA3 transcriptional activation domain includes the sequence shown in amino acids 1379 to 1426 in SEQ NO.1, the amino acid sequence of the FOXO3 transcriptional activation domain includes the sequence shown in amino acids 1433 to 1473 in SEQ NO.1, the amino acid sequence of the ZN473 transcriptional activation domain includes the sequence shown in amino acids 1480 to 1520 in SEQ NO.1, the amino acid sequence of the p65 transcriptional activation domain includes the sequence shown in amino acids 1526 to 1706 in SEQ NO.1, the amino acid sequence of the HSF1 transcriptional activation domain includes the sequence shown in amino acids 1715 to 1838 in SEQ NO.1, the amino acid sequence of the CITED2 transcriptional activation domain includes the sequence shown in amino acids 1379 to 1438 in SEQ NO.3, the amino acid sequence of the MRTF-A transcriptional activation domain includes the sequence shown in SEQ NO. The amino acid sequence of the STAT1 transcriptional activation domain includes the sequence shown from amino acid position 1633 to amino acid position 1668 in SEQ NO.3, and the amino acid sequence of the eNRF2 transcriptional activation domain includes the sequence shown from amino acid position 1671 to amino acid position 1733 in SEQ NO.
3.
6. Humanized CRISPRa system, It is characterized in that It comprises the fusion protein according to any one of claims 1 to 5, and one or more guide RNAs.
7. The CRISPRa system according to claim 6, It is characterized in that The guide RNA includes a fragment that recognizes the target gene. Under the guidance of the guide RNA, the fusion protein can be located in a region within 500 base pairs upstream or downstream of the transcription start site of the target gene; Optionally, the target gene includes at least one of TTN, HBG, NEUROD1, ASCL1, IL1B and SOX2.
8. Host cells, It is characterized in that Comprising the CRISPRa system of claim 6 or 7, and a target gene recognized by the guide RNA contained in the genome of the host cell.
9. Isolated nucleic acids, It is characterized in that It comprises a nucleic acid encoding the fusion protein according to any one of claims 1 to 5, and optionally, further comprises the guide RNA in the CRISPRa system according to claim 6.
10. Carrier, It is characterized in that It contains the nucleic acid according to claim 9.
11. A method for activating transcription of a target gene in a host, It is characterized in that The method comprises the step of introducing the CRISPRa system of claim 6 or 7, the nucleic acid of claim 9, or the vector of claim 10 into a host.
12. Use of the fusion protein of any one of claims 1 to 5, the CRISPRa system of any one of claims 6 or 7, the host cell of claim 8, the nucleic acid of claim 9, or the vector of claim 10 in the preparation of a gene therapy drug.
13. Pharmaceutical composition, It is characterized in that Comprising the fusion protein of any one of claims 1 to 5, the CRISPRa system of any one of claims 6 or 7, the host cell of claim 8, the nucleic acid of claim 9 or the vector of claim 10, and a pharmaceutically acceptable carrier.
